Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted Massed Prolonged Exposure for PTSD
NCT06117306Phase 3Active, not recruiting
- Start
- Oct 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of midomafetamine in post-traumatic stress disorder (PTSD) (2 arms). Primary endpoint: Clinician-rated PTSD symptoms at 4 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06117306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06117306.